Report cover image

Global Epirubicin Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 195 Pages
SKU # APRC20557311

Description

Summary

According to APO Research, the global Epirubicin market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Epirubicin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Epirubicin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Epirubicin market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Epirubicin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Epirubicin market include TEVA, Xinshidai Pharma, Mylan, Pfizer, Salius, Miracalus Pharma, Areva Pharma, Anishya Pharma and Actavis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Epirubicin, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Epirubicin, also provides the sales of main regions and countries. Of the upcoming market potential for Epirubicin, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Epirubicin sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Epirubicin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Epirubicin sales, projected growth trends, production technology, application and end-user industry.

Epirubicin Segment by Company

TEVA
Xinshidai Pharma
Mylan
Pfizer
Salius
Miracalus Pharma
Areva Pharma
Anishya Pharma
Actavis
Epirubicin Segment by Type

50mg/Vial
200mg/Vial
100mg/Vial
Epirubicin Segment by Application

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Epirubicin Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Epirubicin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Epirubicin market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Epirubicin significant trends, drivers, influence factors in global and regions.
6. To analyze Epirubicin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Epirubicin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Epirubicin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Epirubicin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Epirubicin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Epirubicin industry.
Chapter 3: Detailed analysis of Epirubicin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Epirubicin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Epirubicin in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

195 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Epirubicin Sales Value (2020-2031)
1.2.2 Global Epirubicin Sales Volume (2020-2031)
1.2.3 Global Epirubicin Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Epirubicin Market Dynamics
2.1 Epirubicin Industry Trends
2.2 Epirubicin Industry Drivers
2.3 Epirubicin Industry Opportunities and Challenges
2.4 Epirubicin Industry Restraints
3 Epirubicin Market by Company
3.1 Global Epirubicin Company Revenue Ranking in 2024
3.2 Global Epirubicin Revenue by Company (2020-2025)
3.3 Global Epirubicin Sales Volume by Company (2020-2025)
3.4 Global Epirubicin Average Price by Company (2020-2025)
3.5 Global Epirubicin Company Ranking (2023-2025)
3.6 Global Epirubicin Company Manufacturing Base and Headquarters
3.7 Global Epirubicin Company Product Type and Application
3.8 Global Epirubicin Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Epirubicin Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Epirubicin Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Epirubicin Market by Type
4.1 Epirubicin Type Introduction
4.1.1 50mg/Vial
4.1.2 200mg/Vial
4.1.3 100mg/Vial
4.2 Global Epirubicin Sales Volume by Type
4.2.1 Global Epirubicin Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Epirubicin Sales Volume by Type (2020-2031)
4.2.3 Global Epirubicin Sales Volume Share by Type (2020-2031)
4.3 Global Epirubicin Sales Value by Type
4.3.1 Global Epirubicin Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Epirubicin Sales Value by Type (2020-2031)
4.3.3 Global Epirubicin Sales Value Share by Type (2020-2031)
5 Epirubicin Market by Application
5.1 Epirubicin Application Introduction
5.1.1 Hospital Pharmacies
5.1.2 Online Pharmacies
5.1.3 Retail Pharmacies
5.2 Global Epirubicin Sales Volume by Application
5.2.1 Global Epirubicin Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Epirubicin Sales Volume by Application (2020-2031)
5.2.3 Global Epirubicin Sales Volume Share by Application (2020-2031)
5.3 Global Epirubicin Sales Value by Application
5.3.1 Global Epirubicin Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Epirubicin Sales Value by Application (2020-2031)
5.3.3 Global Epirubicin Sales Value Share by Application (2020-2031)
6 Epirubicin Regional Sales and Value Analysis
6.1 Global Epirubicin Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Epirubicin Sales by Region (2020-2031)
6.2.1 Global Epirubicin Sales by Region: 2020-2025
6.2.2 Global Epirubicin Sales by Region (2026-2031)
6.3 Global Epirubicin Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Epirubicin Sales Value by Region (2020-2031)
6.4.1 Global Epirubicin Sales Value by Region: 2020-2025
6.4.2 Global Epirubicin Sales Value by Region (2026-2031)
6.5 Global Epirubicin Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Epirubicin Sales Value (2020-2031)
6.6.2 North America Epirubicin Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Epirubicin Sales Value (2020-2031)
6.7.2 Europe Epirubicin Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Epirubicin Sales Value (2020-2031)
6.8.2 Asia-Pacific Epirubicin Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Epirubicin Sales Value (2020-2031)
6.9.2 South America Epirubicin Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Epirubicin Sales Value (2020-2031)
6.10.2 Middle East & Africa Epirubicin Sales Value Share by Country, 2024 VS 2031
7 Epirubicin Country-level Sales and Value Analysis
7.1 Global Epirubicin Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Epirubicin Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Epirubicin Sales by Country (2020-2031)
7.3.1 Global Epirubicin Sales by Country (2020-2025)
7.3.2 Global Epirubicin Sales by Country (2026-2031)
7.4 Global Epirubicin Sales Value by Country (2020-2031)
7.4.1 Global Epirubicin Sales Value by Country (2020-2025)
7.4.2 Global Epirubicin Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Epirubicin Sales Value Growth Rate (2020-2031)
7.5.2 USA Epirubicin Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Epirubicin Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Epirubicin Sales Value Growth Rate (2020-2031)
7.6.2 Canada Epirubicin Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Epirubicin Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Epirubicin Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Epirubicin Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Epirubicin Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Epirubicin Sales Value Growth Rate (2020-2031)
7.8.2 Germany Epirubicin Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Epirubicin Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Epirubicin Sales Value Growth Rate (2020-2031)
7.9.2 France Epirubicin Sales Value Share by Type, 2024 VS 2031
7.9.3 France Epirubicin Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Epirubicin Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Epirubicin Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Epirubicin Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Epirubicin Sales Value Growth Rate (2020-2031)
7.11.2 Italy Epirubicin Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Epirubicin Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Epirubicin Sales Value Growth Rate (2020-2031)
7.12.2 Spain Epirubicin Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Epirubicin Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Epirubicin Sales Value Growth Rate (2020-2031)
7.13.2 Russia Epirubicin Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Epirubicin Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Epirubicin Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Epirubicin Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Epirubicin Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Epirubicin Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Epirubicin Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Epirubicin Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Epirubicin Sales Value Growth Rate (2020-2031)
7.16.2 China Epirubicin Sales Value Share by Type, 2024 VS 2031
7.16.3 China Epirubicin Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Epirubicin Sales Value Growth Rate (2020-2031)
7.17.2 Japan Epirubicin Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Epirubicin Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Epirubicin Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Epirubicin Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Epirubicin Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Epirubicin Sales Value Growth Rate (2020-2031)
7.19.2 India Epirubicin Sales Value Share by Type, 2024 VS 2031
7.19.3 India Epirubicin Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Epirubicin Sales Value Growth Rate (2020-2031)
7.20.2 Australia Epirubicin Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Epirubicin Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Epirubicin Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Epirubicin Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Epirubicin Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Epirubicin Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Epirubicin Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Epirubicin Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Epirubicin Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Epirubicin Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Epirubicin Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Epirubicin Sales Value Growth Rate (2020-2031)
7.24.2 Chile Epirubicin Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Epirubicin Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Epirubicin Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Epirubicin Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Epirubicin Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Epirubicin Sales Value Growth Rate (2020-2031)
7.26.2 Peru Epirubicin Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Epirubicin Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Epirubicin Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Epirubicin Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Epirubicin Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Epirubicin Sales Value Growth Rate (2020-2031)
7.28.2 Israel Epirubicin Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Epirubicin Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Epirubicin Sales Value Growth Rate (2020-2031)
7.29.2 UAE Epirubicin Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Epirubicin Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Epirubicin Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Epirubicin Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Epirubicin Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Epirubicin Sales Value Growth Rate (2020-2031)
7.31.2 Iran Epirubicin Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Epirubicin Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Epirubicin Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Epirubicin Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Epirubicin Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 TEVA
8.1.1 TEVA Comapny Information
8.1.2 TEVA Business Overview
8.1.3 TEVA Epirubicin Sales, Value and Gross Margin (2020-2025)
8.1.4 TEVA Epirubicin Product Portfolio
8.1.5 TEVA Recent Developments
8.2 Xinshidai Pharma
8.2.1 Xinshidai Pharma Comapny Information
8.2.2 Xinshidai Pharma Business Overview
8.2.3 Xinshidai Pharma Epirubicin Sales, Value and Gross Margin (2020-2025)
8.2.4 Xinshidai Pharma Epirubicin Product Portfolio
8.2.5 Xinshidai Pharma Recent Developments
8.3 Mylan
8.3.1 Mylan Comapny Information
8.3.2 Mylan Business Overview
8.3.3 Mylan Epirubicin Sales, Value and Gross Margin (2020-2025)
8.3.4 Mylan Epirubicin Product Portfolio
8.3.5 Mylan Recent Developments
8.4 Pfizer
8.4.1 Pfizer Comapny Information
8.4.2 Pfizer Business Overview
8.4.3 Pfizer Epirubicin Sales, Value and Gross Margin (2020-2025)
8.4.4 Pfizer Epirubicin Product Portfolio
8.4.5 Pfizer Recent Developments
8.5 Salius
8.5.1 Salius Comapny Information
8.5.2 Salius Business Overview
8.5.3 Salius Epirubicin Sales, Value and Gross Margin (2020-2025)
8.5.4 Salius Epirubicin Product Portfolio
8.5.5 Salius Recent Developments
8.6 Miracalus Pharma
8.6.1 Miracalus Pharma Comapny Information
8.6.2 Miracalus Pharma Business Overview
8.6.3 Miracalus Pharma Epirubicin Sales, Value and Gross Margin (2020-2025)
8.6.4 Miracalus Pharma Epirubicin Product Portfolio
8.6.5 Miracalus Pharma Recent Developments
8.7 Areva Pharma
8.7.1 Areva Pharma Comapny Information
8.7.2 Areva Pharma Business Overview
8.7.3 Areva Pharma Epirubicin Sales, Value and Gross Margin (2020-2025)
8.7.4 Areva Pharma Epirubicin Product Portfolio
8.7.5 Areva Pharma Recent Developments
8.8 Anishya Pharma
8.8.1 Anishya Pharma Comapny Information
8.8.2 Anishya Pharma Business Overview
8.8.3 Anishya Pharma Epirubicin Sales, Value and Gross Margin (2020-2025)
8.8.4 Anishya Pharma Epirubicin Product Portfolio
8.8.5 Anishya Pharma Recent Developments
8.9 Actavis
8.9.1 Actavis Comapny Information
8.9.2 Actavis Business Overview
8.9.3 Actavis Epirubicin Sales, Value and Gross Margin (2020-2025)
8.9.4 Actavis Epirubicin Product Portfolio
8.9.5 Actavis Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Epirubicin Value Chain Analysis
9.1.1 Epirubicin Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Epirubicin Sales Mode & Process
9.2 Epirubicin Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Epirubicin Distributors
9.2.3 Epirubicin Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.